| Literature DB >> 2373343 |
S P Sidorenko, E P Vetrova, O V Iurchenko, L N Shlapatskaia, A G Berdova, A M Elenskaia, M D Bal'shin, D F Gluzman.
Abstract
The authors have developed a panel of monoclonal antibodies (MCA) of IPO series (Institute of Problems of Oncology, Kiev). RPMI-1788 cell line, Daudi, as well as splenocytes of a patient with hairy-cell leukemia were used for immunization of mice. It has been shown that IPO-3, IPO-10 and IPO-24 MCA are directed against differentiation antigens of human B-lymphocytes. IPO-4 MCA reveal the antigen of activated T- and B-cells. IPO-5 and IPO-20 MCA recognize HLA-ABC, while IPO-37 a common leucocytic antigen. IPO-38 MCA are directed against the nuclear antigen. The possibilities of using IPO MCA in hematology have been discussed.Entities:
Mesh：
Substances：
Year: 1990 PMID： 2373343
Source DB: PubMed Journal: Gematol Transfuziol ISSN： 0234-5730 Impact factor: 0.172